drugset
drugset / Trial / NCT04565171

Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD

NCT04565171 ↗

Phase 1 Completed 16 enrolled Sunshine Lake Pharma Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is to evaluate the single-dose pharmacokinetics (PK) and safety of Yimitasvir phosphate capsule in participants with End-stage renal disease without hemodialysis using matched healthy participants as a control group.

Timeline

Start
2021-04-15
Primary completion
2022-05-07
Completion
2022-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Yimitasvir Small molecule 100 mg Oral

Indications

impaired renal function disease